Abstract: Uterine leiomyosarcoma (uLMS) is a rare uterine interstitial tumor with a low incidence and a high malignant tumor. Even with early treatment, uLMS still has a highly by recurrence rate and metastasis risk. The preoperative diagnosis of the disease is difficult, not like cervical cancer, endometrial cancer has good diagnostic tools, intraoperative existence of inappropriate treatment or inadequate treatment way, so the disease prognosis is poor. Surgical treatment is still the main treatment of the disease, postoperative adjuvant treatment has a lot of scheme, for example adjuant radiation therapy, chemotherapy, targeted therapy, combination treatment or follow-up observation. Due to low morbidity, low number of studies and rapid disease progression, there is still no unified standard solution, and the efficacy of adjuvant therapy is not ideal, with few clinical benefits. This paper discusses the knowledge of systematic treatment of uLMS, especially in the treatment of adjuvant therapy, metastatic lesion and accidental discovery of this disease, providing reference for clinical treatment.

Key words: Uterine neoplasms, Leiomyosarcoma, Antineoplastic combined chemotherapy protocols, Antineoplastic protocols